Monday, November 28, 2016 7:28:02 AM
Nov 28 (Reuters) - Idera Pharmaceuticals Inc(IDRA) :
* Press release - Idera Pharmaceuticals(IDRA) and Vivelix Pharmaceuticals, Ltd. Enter into exclusive license agreement for the worldwide rights to IMO-9200
* Idera Pharmaceuticals Inc(IDRA) - under terms of agreement, idera will receive an upfront fee of $15 million
* Idera Pharmaceuticals Inc(IDRA) - will be eligible for future imo-9200 related development, regulatory and sales milestone payments totaling up to $140 million
* Idera Pharmaceuticals Inc(IDRA) - will be eligible for escalating royalties ranging from mid single-digits to low double-digits of global net sales
* Idera Pharmaceuticals Inc(IDRA) -under terms, idera is responsible for developing potential back-up compounds to imo-9200
* Idera Pharmaceuticals(IDRA) - idera will be eligible for related development, regulatory sales and milestone payments totaling up to $52.5 million
* Idera Pharmaceuticals Inc(IDRA) - as part of agreement, idera has agreed to create and characterize potential back-up compounds for vivelix Source text for Eikon: Further company coverage:
(c) Copyright Thomson Reuters 2016. Click For Restrictions - about.reuters.com/fulllegal.asp
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM